Pfizer (NYSE:PFE) will pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer ...
Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac. The ...
, opens new tab has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people ...
Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, according to people familiar with the deal, the biggest of the litigation.
Pfizer has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, according to people familiar with the deal, the biggest of the litigation.
Despite this significant resolution, the settlement does not completely absolve Pfizer from its Zantac-related legal challenges. Concerns surrounding potential liabilities stemming from Zantac ...
Pfizer Inc (NYSE:PFE) released longer-term follow-up results from the Phase 3 CROWN trial evaluating Lorbrena (lorlatinib) ...
Pfizer (NYSE:PFE) has reportedly agreed to pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer risks associated with its now-discontinued heartburn ...
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with ...
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with ...
Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, according to people familiar with the deal, the biggest of the litigation.